Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Regulatory News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 110.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.20 (0.182%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 110.00
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of shares pursuant to Incentive Scheme

9 Jul 2020 13:00

RNS Number : 5757S
Syncona Limited
09 July 2020
 

Syncona Limited

Issue of shares pursuant to Incentive Scheme and PDMR dealings

9 July 2020

Syncona Limited (the "Company") today announces that a total of 914,880 new ordinary shares (representing 0.14% of the Company's existing issued ordinary shares) will be issued in satisfaction of realisations under the Company's long term Incentive Scheme. The new ordinary shares, when issued, will rank pari passu with the existing issued ordinary shares of the Company. In accordance with the rules of the Incentive Scheme, the number of ordinary shares to be issued has been calculated using the closing mid-market price on 8 July 2020, 257.5p.

In accordance with the rules of the Incentive Scheme, ordinary shares delivered on realisation may not be sold or transferred by the recipient for a period of one year following the realisation date.

The issue of shares include the following shares to be issued to senior members of the Syncona Investment Management Limited (SIML) leadership team:

Name

SIML Title

No. of shares to be issued

Martin Murphy

Chief Executive Officer

338,055

Chris Hollowood

Chief Investment Officer

200,269

John Bradshaw

Chief Financial Officer

56,219

Application has been made to the Financial Conduct Authority for the shares to be admitted to the Official List, and to the London Stock Exchange for the shares to be admitted to trading and it is expected that dealings will commence in the new ordinary shares on 15 July 2020.

Following admission, the Company will have 664,580,417 ordinary shares in issue and the total number of voting rights in the Company will be 664,580,417. The Company does not hold any ordinary shares in treasury. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interests in, the Company under the FCA's Disclosure and Transparency Rules.

Notification of transactions by Persons Discharging Managerial Responsibilities ("PDMRs") are set out below.

[ENDS]

Enquiries

FTI Consulting

Ben Atwell / Natalie Garland-Collins

Tel: +44 (0) 20 3727 1000

 

Syncona Ltd

Siobhan Weaver / Annabel Clay

Tel : +44 (0) 20 3981 7940

Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com

About Syncona

Syncona is a leading FTSE250 healthcare company focused on founding, building and funding a portfolio of global leaders in life science. Our vision is to build a sustainable, diverse portfolio of 15 - 20 companies focused on delivering transformational treatments to patients in truly innovative areas of healthcare, through which we are seeking to deliver strong risk-adjusted returns for shareholders.

 

We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses. We take a long-term view, underpinned by a strategic capital base which provides us with control and flexibility over the management of our portfolio. We focus on delivering dramatic efficacy for patients in areas of high unmet need.

 

1.

Details of PDMR / person closely associated with them ("PCA")

a)

Name

Martin Murphy

b)

Position / status

Chief Executive Officer, SIML

c)

Initial notification / amendment

Initial Notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary shares 

GG00B8P59C08

b)

Nature of the transaction

Issue of shares pursuant to the Syncona long term Incentive Scheme

c)

Price(s) and volume(s)

Price(s)

257.5p

Volume(s)

338,055

d)

Aggregated information

Aggregated volume

Price

 

 

N/A

e)

Date of the transaction

9 July 2020

f)

Place of the transaction

Outside a trading venue

g)

Currency

GBP - British Pound

 

1.

Details of PDMR / person closely associated with them ("PCA")

a)

Name

Chris Hollowood

b)

Position / status

Chief Investment Officer, SIML

c)

Initial notification / amendment

Initial Notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary shares 

GG00B8P59C08

b)

Nature of the transaction

Issue of shares pursuant to the Syncona long term Incentive Scheme

c)

Price(s) and volume(s)

Price(s)

257.5p

Volume(s)

200,269

d)

Aggregated information

Aggregated volume

Price

 

 

N/A

e)

Date of the transaction

9 July 2020

f)

Place of the transaction

Outside a trading venue

g)

Currency

GBP - British Pound

 

1.

Details of PDMR / person closely associated with them ("PCA")

a)

Name

John Bradshaw

b)

Position / status

Chief Financial Officer, SIML

c)

Initial notification / amendment

Initial Notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary shares 

GG00B8P59C08

b)

Nature of the transaction

Issue of shares pursuant to the Syncona long term Incentive Scheme

c)

Price(s) and volume(s)

Price(s)

257.5p

Volume(s)

56,219

d)

Aggregated information

Aggregated volume

Price

 

 

N/A

e)

Date of the transaction

9 July 2020

f)

Place of the transaction

Outside a trading venue

g)

Currency

GBP - British Pound

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHRLMBTMTAMBLM
Date   Source Headline
13th Jun 20247:00 amRNSTransaction in Own Shares
12th Jun 20247:00 amRNSTransaction in Own Shares
11th Jun 20247:00 amRNSTransaction in Own Shares
10th Jun 20247:00 amRNSTransaction in Own Shares
7th Jun 20247:00 amRNSTransaction in Own Shares
6th Jun 20247:00 amRNSTransaction in Own Shares
5th Jun 20247:00 amRNSQuell provides clinical updates on QEL-001
5th Jun 20247:00 amRNSTransaction in Own Shares
4th Jun 20247:00 amRNSTransaction in Own Shares
3rd Jun 20243:18 pmRNSTotal Voting Rights
3rd Jun 20247:00 amRNSTransaction in Own Shares
31st May 20241:51 pmRNSAutolus presents FELIX data at ASCO
31st May 20247:00 amRNSTransaction in Own Shares
30th May 20247:00 amRNSTransaction in Own Shares
29th May 20247:00 amRNSTransaction in Own Shares
28th May 20247:00 amRNSTransaction in Own Shares
24th May 20247:00 amRNSTransaction in Own Shares
23rd May 20247:00 amRNSNotice of Results
23rd May 20247:00 amRNSTransaction in Own Shares
22nd May 20247:00 amRNSTransaction in Own Shares
21st May 20247:00 amRNSTransaction in Own Shares
20th May 20247:00 amRNSTransaction in Own Shares
17th May 202412:05 pmRNSAutolus reports Q1 2024 Financial Results
17th May 20247:00 amRNSTransaction in Own Shares
16th May 20247:00 amRNSTransaction in Own Shares
15th May 20247:00 amRNSTransaction in Own Shares
14th May 20247:00 amRNSTransaction in Own Shares
13th May 20247:00 amRNSTransaction in Own Shares
10th May 20247:00 amRNSTransaction in Own Shares
9th May 202411:05 amRNSFreeline presents clinical data update
9th May 20247:00 amRNSTransaction in Own Shares
8th May 202412:11 pmRNSAchilles reports Q1 2024 Financial Results
8th May 20247:00 amRNSTransaction in Own Shares
7th May 20247:00 amRNSTransaction in Own Shares
3rd May 20247:00 amRNSTransaction in Own Shares
2nd May 20247:00 amRNSTransaction in Own Shares
1st May 20242:14 pmRNSTotal Voting Rights
1st May 20247:00 amRNSTransaction in Own Shares
30th Apr 20247:00 amRNSTransaction in Own Shares
29th Apr 20247:00 amRNSTransaction in Own Shares
25th Apr 20247:00 amRNSTransaction in Own Shares
24th Apr 20247:00 amRNSTransaction in Own Shares
23rd Apr 20247:00 amRNSTransaction in Own Shares
22nd Apr 20247:00 amRNSTransaction in Own Shares
19th Apr 20247:00 amRNSTransaction in Own Shares
18th Apr 20247:00 amRNSTransaction in Own Shares
17th Apr 20247:00 amRNSTransaction in Own Shares
16th Apr 20247:00 amRNSTransaction in Own Shares
15th Apr 20247:00 amRNSTransaction in Own Shares
12th Apr 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.